Novel point mutations attenuate autotaxin activity.
BACKGROUND
The secreted enzyme autotaxin (ATX) stimulates tumor cell migration, tumorigenesis, angiogenesis, and metastasis. ATX hydrolyzes nucleotides, but its hydrolysis of lysophospholipids to produce lysophosphatidic acid (LPA) accounts for its biological activities. ATX has been identified only as a constitutively active enzyme, and regulation of its activity is largely unexplored. In spite of its presence in plasma along with abundant putative substrate LPC, the product LPA is found in plasma at unexpectedly low concentrations. It is plausible that the LPA-producing activity of ATX is regulated by its expression and by access to substrate(s). For this reason studying the interaction of enzyme with substrate is paramount to understanding the regulation of LPA production.


RESULTS
In this study we determine ATX hydrolytic activities toward several artificial and natural substrates. Two novel point mutations near the enzyme active site (H226Q and H434Q) confer attenuated activity toward all substrates tested. The Vmax for LPC compounds depends upon chain length and saturation; but this order does not differ among wild type and mutants. However the mutant forms show disproportionately low activity toward two artificial substrates, pNpTMP and FS-3. The mutant forms did not significantly stimulate migration responses at concentrations that produced a maximum response for WT-ATX, but this defect could be rescued by inclusion of exogenous LPC.


CONCLUSIONS
H226Q-ATX and H434Q-ATX are the first point mutations of ATX/NPP2 demonstrated to differentially impair substrate hydrolysis, with hydrolysis of artificial substrates being disproportionately lower than that of LPC. This implies that H226 and H434 are important for substrate interaction. Assays that rely on hydrolyses of artificial substrates (FS-3 and pNpTMP), or that rely on hydrolysis of cell-derived substrate, might fail to detect certain mutated forms of ATX that are nonetheless capable of producing LPA in the presence of sufficient exogenous substrate. H420Q-ATX could not be differentiated from WT-ATX, indicating that histidine at position 420 is not required for any of the activities of ATX tested in this study.
Koh
Eunjin
E
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1500, USA. ek4a@virginia.edu
Bandle
Russell W
RW
Roberts
David D
DD
Stracke
Mary L
ML
Clair
Timothy
T
D019943:Amino Acid Substitution / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis / Q000187:drug effects; D015151:Immunoblotting; D007700:Kinetics; D008246:Lysophospholipids / Q000494:pharmacology; D009097:Multienzyme Complexes / Q000235:genetics* / Q000378:metabolism*; D050505:Mutant Proteins / Q000235:genetics / Q000378:metabolism*; D043264:Phosphodiesterase I / Q000235:genetics* / Q000378:metabolism*; D010727:Phosphoric Diester Hydrolases; D017354:Point Mutation / Q000235:genetics*; D011755:Pyrophosphatases / Q000235:genetics* / Q000378:metabolism*; D013379:Substrate Specificity / Q000187:drug effects; D000099189:Lysophospholipase D
D005227:Fatty Acids; D008246:Lysophospholipids; D009097:Multienzyme Complexes; D050505:Mutant Proteins; D043264:Phosphodiesterase I; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases; D000099189:Lysophospholipase D